0.03
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kane Biotech
Its shares trade on TSX Venture under the ticker KNE.V. It has been listed since 7 May 2003. In the fiscal year to 31 December 2025, it reported revenue of C$427,869 and a net loss of C$2.7m. At that date it held total assets of C$2.7m and shareholders' equity of −C$746,545.
Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The firm is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. The company also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 May 2003
- Website
- kanebiotech.com ↗
Leadership
Pay as last reported
- Mr. Philip RenaudChairman of the Board, since 2010C$44,726
- Dr. Robert HuizingaInterim Chief Executive Officer, Director, since 2024
- Mr. Raymond DupuisChief Financial OfficerC$231,389
- Ms. Lori ChristofalosVice President - Quality & Compliance
- Ms. Wendy NachtigallDirector of Marketing
- Mr. Dena MehrabanGeneral Manager of STEM Animal HealthC$178,655
- Dr. John ColemanLead Independent DirectorC$2,250
- Ms. Anne GrevenDirector
- Dr. David KideckelDirector
- Mr. Shameze RampertabDirector
- Ms. Nicole SendeyInvestor Relations, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kane Biotech's StrixNB prevents microbial biofilms in medical devices.
- DispersinB is used for chronic wound care applications in the Wound Care & Surgical division.
- bluestem product line includes water additives, chews, spray, and dental wipes for animal health.
Weaknesses
- Kane Biotech's IPO was on 7 May 2003, a long time ago.
- The company has only one headquarters city, Winnipeg, Manitoba.
- Kane Biotech's products are limited to microbial biofilm prevention and removal.
Opportunities
- Kane Biotech's Coactiv+ is in development for antimicrobial wound rinse and surgical hydrogel.
- The company's bluestem product line targets animal health markets.
- Kane Biotech's DermaKB Biofilm is used for biofilm removal in medical applications.
Threats
- Kane Biotech's DispersinB Gel is in development for prosthetic joint infection applications.
- The company's Wound Care & Surgical division focuses on chronic wound care only.
- Kane Biotech's primary market is animal health, which is a niche segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.